AC Immune (ACIU) Competitors

AC Immune (NASDAQ:ACIU) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Does the media favor ACIU or TRVI?

In the previous week, Trevi Therapeutics had 1 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Trevi Therapeutics and 4 mentions for AC Immune. AC Immune's average media sentiment score of 1.54 beat Trevi Therapeutics' score of 1.42 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ACIU or TRVI more profitable?

AC Immune's return on equity of -28.26% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	N/A	-28.26%	-18.98%
Trevi Therapeutics	N/A	-63.31%	-57.06%

Do analysts prefer ACIU or TRVI?

AC Immune currently has a consensus target price of $12.00, suggesting a potential upside of 593.64%. Trevi Therapeutics has a consensus target price of $17.56, suggesting a potential upside of 154.16%. Given AC Immune's higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Trevi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.30

Does the MarketBeat Community believe in ACIU or TRVI?

AC Immune received 154 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. However, 67.95% of users gave Trevi Therapeutics an outperform vote while only 62.65% of users gave AC Immune an outperform vote.

Company	Underperform	Outperform
AC Immune	Outperform Votes 260 62.65%	Underperform Votes 155 37.35%
Trevi Therapeutics	Outperform Votes 106 67.95%	Underperform Votes 50 32.05%

Which has higher valuation and earnings, ACIU or TRVI?

Trevi Therapeutics has lower revenue, but higher earnings than AC Immune. Trevi Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$27.31M	6.36	-$60.41M	-$0.58	-2.98
Trevi Therapeutics	N/A	N/A	-$29.07M	-$0.47	-14.70

Which has more risk & volatility, ACIU or TRVI?

AC Immune has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of ACIU or TRVI?

51.4% of AC Immune shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Trevi Therapeutics beats AC Immune on 9 of the 17 factors compared between the two stocks.